Response to “Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence”

Groenland, Stefanie L.; Geel, Dieuwertje R.; Beijnen, Jos H.; Smit, Egbert F.; Huitema, Alwin D.R.; Steeghs, Neeltje

doi:https://doi.org/10.1002/cpt.2372

Response to “Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence”

DSpace/Manakin Repository

Response to “Optimized Alectinib Dose Regimen for Treatment of Patients With ALK-Positive NSCLC Based on Robust Pharmacometric Analyses and Clinical Evidence”

Groenland, Stefanie L.; Geel, Dieuwertje R.; Beijnen, Jos H.; Smit, Egbert F.; Huitema, Alwin D.R.; Steeghs, Neeltje

(2021) Clinical Pharmacology and Therapeutics, volume 110, issue 5, pp. 1164 - 1164

(Comment)

Download/Full Text

The full text of this publication is not available.

Version on publisher website for UU-students and staff

Version on publisher website

Keywords: Carbazoles, Humans, Lung Neoplasms/drug therapy, Piperidines/adverse effects, Receptor Protein-Tyrosine Kinases, Pharmacology (medical), Pharmacology, Comment, Letter

DOI: https://doi.org/10.1002/cpt.2372

ISSN: 0009-9236

Publisher: Nature Publishing Group

Note: Funding Information: No funding was received for this work.

(Peer reviewed)